[{"orgOrder":0,"company":"Clock.bio","sponsor":"LocalGlobe","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"iPSC-based Cell Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Clock.bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Clock.bio \/ LocalGlobe","highestDevelopmentStatusID":"12","companyTruncated":"Clock.bio \/ LocalGlobe"}]

Find Clinical Drug Pipeline Developments & Deals by Clock.bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The seed funding enabled clock.bio to generate its Atlas of Rejuvenation Factors across the entire human genome and identified several potential gene therapy targets for rejuvenation.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 09, 2024

                          Lead Product(s) : iPSC-based Cell Therapy

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : LocalGlobe

                          Deal Size : $5.3 million

                          Deal Type : Financing

                          blank